The adaptive immune system’s role in cancer immunosurveillance is well established and plays a crucial role for most cancer immunotherapies such as immune checkpoint inhibitors for example anti-PD1 (pembrolizumab and nivolumab) and CTLA-4 inhibitors (ipilimumab) (2, 3). The gene discussed is CTLA4; the disease is cancer.